A randomised, double-blind, parallel-group, dose finding study to assess the efficacy and safety of ZD6474 in patients with advanced, metastatic, or recurrent NSCLC who have failed previous chemotherapy regimens, at least one of which contained platinum

Trial Profile

A randomised, double-blind, parallel-group, dose finding study to assess the efficacy and safety of ZD6474 in patients with advanced, metastatic, or recurrent NSCLC who have failed previous chemotherapy regimens, at least one of which contained platinum

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Apr 2008 Results published in the Journal of Clinical Oncology, April, 2008.
    • 28 Jun 2007 Status changed from in progress to completed.
    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top